Back to results
US 2004/0034011 A1Published application
Derivatives of naphthalene with comt inhibiting activity
AssigneeOrion Corporation
InventorsReijo Bäckström, Jarmo Pystynen, Timo Lotta, Martti Ovaska, Jyrki Taskinen
Life of this patent
Estimating the term…
Abstract
Compounds of formula (I′), wherein A, R1 to R3 and t are as defined in the disclosure, exhibit COMT enzyme inhibiting activity so that they are useful as COMT inhibitors.
Claims17
A compound of formula I,
- 12
- wherein the two OH— substituents in the phenyl moiety are in a position ortho to one another and R1 in a position ortho to one of the hydroxy groups;
- and wherein
- “A” is a fused ring moiety selected from benzo ring and a 6-membered heteroaromatic ring which contains one or two N heteroatoms;
- t is 1, 2, 3 or 4;
- R1 is NO2, CN, CHO or CF3;
- and
- each R2 is selected independently from OH, halogen, NO2, SH, NH2, (C1-C6)alkyl, (C2-C6)alkenyl, (C1-C6)alkoxy, OH—(C1-C6)alkyl, NH2—(C1-C6)alkyl, halo-(C1-C6)alkyl, mono- or di(C1-C6)alkylamino, SO2R4, (C1-C20)alkyl-CO—, halo-(C1-C6)alkyl-CO—, phenyl-N═N— optionally substituted with one to three substituents R6, —(Y)n—(B)m—COOH and —(Y)n—(B)m—R5;
- R3 is H, NO2, CN, CHO, halogen, CF3 or CH3;
- and
- R4 is (C1-C6)alkyl, NH2, OH or mono- or di(C1-C6)alkylamino;
- m is 0 or 1;
- n is O or 1;
- Y is —CO— or —CHOH—;
- B is (C1-C6)alkylene or (C2-C6)alkenylene;
- R5 is phenyl, naphthyl, (C3-C7)cycloalkyl or 5- to 10-membered heterocyclyl with one to four heteroatoms each selected independently from N, O and S, wherein the said phenyl, naphthyl, (C3-C7)cycloalkyl or 5- to 10-membered heterocyclyl is optionally substituted with one to five substituents R6,
- or R5 is
- 13
- each R6 is selected independently from OH, halogen, COOH, 5-tetrazolyl, NO2, SH, NH2, CN, CHO, ═O, (C1-C6)alkyl, (C1-C6)alkoxy, halo-(C1-C6)alkyl, mono- or di(C1-C6)alkylamino, CO—(C1-C6)alkyl, CO—NH2, mono- or di(C1-C6)alkylamino-CO—, NHOH, CONHOH or SO2R4;
- or pharmaceutically acceptable salts or pharmaceutically acceptable esters thereof.
17 more elements
Use of a compound of formula I′:
- 17
- wherein the two OH— substituents in the phenyl moiety are in a position ortho to one another and R1 is in a position ortho to one of the hydroxy groups;
- and wherein
- “A” is a fused ring moiety selected from benzo ring and a 6-membered heteroaromatic ring which contains one or two N heteroatoms;
- R1 is NO2, CN, CHO, CF3 or (C1-C6)alkyl-CO—;
- t is 0, 1, 2, 3 or 4;
- each R2 is selected independently from OH, halogen, NO2, SH, NH2, (C1-C6)alkyl, (C2-C6)alkenyl, (C1-C6)alkoxy, OH—(C1-C6)alkyl, NH2—(C1-C6)alkyl, halo-(C1-C6)alkyl, mono- or di(C1-C6)alkylamino, SO2R4, (C1-C20)alkyl-CO—, halo-(C1-C6)alkyl-CO—, phenyl-N═N— optionally substituted with one to three substituents R6, —(Y)n—(B)m—COOH and —(Y)n—(B)m—R5;
- R3 is H, NO2, CN, CHO, halogen, CF3 or (C1-C6)alkyl;
- and
- R4 is (C1-C6)alkyl, NH2, OH or mono- or di(C1-C6)alkylamino;
- m is 0 or 1;
- n is 0 or 1;
- Y is —CO— or —CHOH—;
- B is (C1-C6)alkylene or (C2-C6)alkenylene;
- R5 is phenyl, naphthyl, (C3-C7)cycloalkyl or 5- to 10-membered heterocyclyl with one to four heteroatoms each selected independently from N, O and S, wherein the said phenyl, naphthyl, (C3-C7)cycloalkyl or 5- to 10-membered heterocyclyl is optionally substituted with one to five substituents R6,
- or R5 is
- 18
- each R6 is selected independently from OH, halogen, COOH, 5-tetrazolyl, NO2, SH, NH2, CN, CHO, ═O, (C1-C6)alkyl, (C1-C6)alkoxy, halo-(C1-C6)alkyl, mono- or di(C1-C6)alkylamino, CO—(C1-C6)alkyl, CO—NH2, mono- or di(C1-C6)alkylamino-CO—, NHOH, CONHOH or SO2R4;
- or pharmaceutically acceptable salts or pharmaceutically acceptable esters thereof, for the manufacture of a medicament as a COMT inhibiting agent.
16 more elements
Dependencies are inferred from the claim text.